Glarizonto Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 7 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 3.00 M
- Revenue Growth 31.31%
- Profit Growth 14.24%
- Ebitda 38.84%
- Net Worth 15.34%
- Total Assets -12.89%
About Glarizonto Pharma
Glarizonto Pharma Private Limited (GPPL) is a Private Limited Indian Non-Government Company incorporated in India on 31 October 2017 (Seven years and three months 15 days old ). Its registered office is in Secunderabad, Telangana, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹3.00 M.
Latha Veettil, Raghu Peediyekal, and Rajesh Parakkel serve as directors at the Company.
Company Details
-
Location
Secunderabad, Telangana, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U24299TG2017PTC120347
-
Company No.
120347
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
31 Oct 2017
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Hyderabad
Industry
Who are the key members and board of directors at Glarizonto Pharma?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Latha Veettil
|
Director | 31-Oct-2017 | Current |
|
Raghu Peediyekal
|
Director | 31-Oct-2017 | Current |
|
Rajesh Parakkel
|
Director | 23-Jul-2018 | Current |
Financial Performance of Glarizonto Pharma.
Glarizonto Pharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 31.31% increase. The company also saw a substantial improvement in profitability, with a 14.24% increase in profit. The company's net worth Soared by an impressive increase of 15.34%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Glarizonto Pharma?
In 2023, Glarizonto Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹3.00 M
₹0
Charges Breakdown by Lending Institutions
- Others : 0.30 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 06 Nov 2020 | Others | ₹3.00 M | Open |
How Many Employees Work at Glarizonto Pharma?
Unlock and access historical data on people associated with Glarizonto Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Glarizonto Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Glarizonto Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.